Australian patent granted for RECCE anti-infectives - TechInvest Magazine Online

Recce Pharmaceuticals (ASX:RCE) has been formally granted the first of of new Patent Family 4 for RECCE’s anti-infectives “Process for Preparation of Biologically Active Copolymer” by the Australian Patent Office

The Australian Patent claims relate to RECCE 327 (R327) and RECCE 529 (R529), most notably:

• Process for preparation of RECCE anti-infectives

• Use of R327/R529 for the treatment of disease, particularly in treatment of bacterial infections, viral infections and more
  • Specifically, further validating RECCE anti-infectives from studies in Burn Wounds, Urinary Tract Infections, Gonorrhoea, Influenza, SARS-CoV- 2 and more (bacterial/viral pathogen examples below)

• Administration by oral, inhalation, transdermal delivery or by injection (into the blood stream, intramuscular and/or intravenous)

• Administration may also be applied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery)

CEO, James Graham, said this is the first of Recce’s wholly owned Family 4 Granted, with Patent Cooperation Treaty Country (PCT) patent submissions in respective stages of review.

“We are thrilled to see this new family of intellectual property be granted in Australia; with further market-monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” he said.

Bacterial Pathogens Covered in Family 4

Specific examples of such bacterial infections may be selected from the group of bacteria consisting of Proteus spp, Serratia spp, Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, coagulase-negative Staphylococcus spp, Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus spp.

Viral Pathogens Covered in Family 4

Examples of viral infections may be caused by a range of viruses such as coated viruses (e.g., lipid coated viruses) including herpes, HIV, cytomegalovirus and influenza. Preferably, the viral infection treated and/or controlled by the method of the invention may be HSV-1, HSV-2, Varicella Zoster Virus (in the form of chicken pox or shingles), HCMV, EBV, Herpes 6, Herpes 7, Herpes 8 and SARS-CoV-2.

Other examples include Influenza A, Ross River virus, Coronavirus including Coronaviruses responsible for severe acute respiratory syndrome and, SARS-CoV-2 also generally referred to as COVID-19.